Autologous Anti-Egfr/Anti-Il13Ralpha2 Car T-Cells
Recurrent Astrocytoma, IDH-Mutant, Grade 4
City of Hope Medical CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Recurrent Astrocytoma, IDH-Mutant, Grade 4 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-IL13Ralpha2 CAR T-cells City of Hope Medical Center | Phase 1 | CC |
Triapine National Cancer Institute (NCI) | Phase 1 | CC |
FLUDEOXYGLUCOSE City of Hope Medical Center | Phase 1 | CC |
Allogeneic Adipose-Derived Mesenchymal Stem Cells Mayo Clinic | Phase 1 | CC |
Same molecule, other indications
Autologous Anti-Egfr/Anti-Il13Ralpha2 Car T-Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →